Lupin Limited (LUPIN)
NSEINR 2060.951.29%
Price Chart
Key Statistics
Market Cap
INR 928.9B
P/E Ratio
32.43
Revenue (TTM)
INR 220.02B
Volume
337.7K
52W High
INR 2402.90
52W Low
INR 1486.78
Dividend Yield
0.40%
Beta
0.58
Technicals
50-Day MA
2060.255
200-Day MA
2045.748
52 Week High
2402.9
52 Week Low
1486.7817
About LUPIN
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of vari.
Employees
19210
Headquarters
Mumbai, India
CEO
Ms. Vinita D. Gupta
Latest News
Lupin’s Firdapse generic wins FDA approval, pending patent resolution - Lambert-Eaton News
Yesterday • Google News
Lupin launches generic heart drug rivaroxaban in US - CNBCTV18
2 weeks ago • Google News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
41.22
Percentile: 86.76
Environmental Risk Score
0.36
Percentile: 1
Social Risk Score
19.59
Percentile: 1
Governance Risk Score
13.27
Percentile: 1
Controversy Level
ESG data provided by Sustainalytics, Inc.
LUPIN
Category Average
3Significant Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg